Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R2JS
|
||||
| Former ID |
DIB016627
|
||||
| Drug Name |
Droloxifene
|
||||
| Synonyms |
E-droloxifene; FK-435; K-060; K-060E; RP-60850; K-21.060E; 3-hydroxytamoxifen
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Breast cancer [ICD9: 174, 175; ICD10:C50] | Discontinued in Phase 2 | [544750] | ||
| Company |
Klinge Pharma GmbH
|
||||
| Formula |
C26H29NO2
|
||||
| Canonical SMILES |
C(=C(\c1ccccc1)/CC)(/c1cc(O)ccc1)\c1ccc(cc1)OCCN(C)C
|
||||
| CAS Number |
CAS 82413-20-5
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Estrogen receptor | Target Info | Modulator | [533830] | |
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Signaling events mediated by HDAC Class II | |||||
| Plasma membrane estrogen receptor signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| FOXA1 transcription factor network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.